La catena delle opzioni mostra i dati chiave delle opzioni azionarie di ReTo Eco-Solutions a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per ReTo Eco-Solutions..

ReTo Eco-Solutions (NASDAQ:RETO) Azioni, Catena delle Opzioni

ReTo Eco-Solutions

ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Machinery and Equipment sales, and Technology Consulting and other services. The company earns its revenue from the Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.

News

Short Ideas

Markets

Trading Ideas

PTVE

RETO

Titoli ipercomprati nel settore delle materie prime: quali sono i rischi e le opportunità per gli investitori? Analisi e previsioni.

Ecco le 3 azioni del settore dei materiali da tenere d&#39;occhio (e perché)

ReTo Eco-Solutions, Inc. - Class A Shares

ReTo Eco-Solutions Inc

Jefferies analyst Julien Dumoulin-Smith upgrades First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) from Hold to Buy and raises the price target from $157 to $192.

Upgrades

Price Target

Analyst Ratings

FSLR

Jefferies Upgrades First Solar to Buy, Raises Price Target to $192

The preclinical program was conducted by Professor Sudha Rao at the renowned QIMR Berghofer Medical Research Institute, revealing how paxalisib can reprogram the tumor microenvironment and enhance immune response, showing substantial synergy with immune checkpoint inhibitors. The data provide strong scientific and translational rationale for continued development of paxalisib as part of immunotherapy-based regimens.
Key Findings
<ul>
<li>Dual targeting of PI3K and mTOR but not PI3K alone inhibits cancer cell proliferation and migration in vitro.</li>
<li>Paxalisib remodels the TNBC tumor microenvironment, increasing CD4+ and CD8+ T cell infiltration and activation</li>
<li>The combination of paxalisib with KEYTRUDA&#xAE; (pembrolizumab) demonstrated synergistic antitumor activity in advanced breast cancer, resulting in robust tumor regression and prolonged survival in preclinical models</li>
<li>The data validate a mechanistic rationale for ongoing clinical exploration of paxalisib in combination with checkpoint inhibitors and PARP inhibitors</li>
</ul>

Biotech

General

KZIA

Kazia Therapeutics Announces Publication Of Preclinical Data On Paxalisib's In Immunotherapy Resistance In Triple-Negative Breast Cancer

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Amplitude (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPL#NASDAQ">AMPL</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $13.58, a high estimate of $16.00, and a low estimate of $10.00. Experiencing a 7.93% decline, the current average is now lower than the previous average price target of $14.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1749643281_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Amplitude. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Amplitude. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Amplitude compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Amplitude's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AMPL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Amplitude analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Amplitude Better</h2>
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
<h3>Amplitude: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Amplitude's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.09% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Amplitude's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -27.81% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amplitude's ROE stands out, surpassing industry averages. With an impressive ROE of -7.59%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Amplitude's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.99%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Amplitude's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPL

What 12 Analyst Ratings Have To Say About Amplitude

Three U.S. lawmakers have disclosed recent purchases of a pet healthcare company just weeks before a biotech bill that could benefit the company's business was introduced in Congress.
What Happened: On Tuesday, Nancy Pelosi Stock Tracker, an X account that monitors U.S. lawmakers&#8217; financial disclosures, reported that Rep. April Delaney (R-MD), Jefferson Shreve (R-IN), and Rob Bresnahan (R-PA) purchased shares of IDEXX Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) in early to mid-April and May.
The timing has drawn scrutiny, as all three lawmakers sit on committees directly tied to the &#8220;National Biotech Initiative Act of 2025,&#8221; a bill aimed at expanding federal funding for biotechnology research and development.
The legislation, introduced on April 9, was referred to several committees, including agriculture and foreign affairs, on which each of the three lawmakers serves.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45877761/ross-gerber-calls-out-warner-bros-discovery-ceo-david-zaslav-saying-hes-created-zero-value-after-the-conglomerate-announced-plans-to-split-into-two-companies-by-2026">Ross Gerber Calls Out Warner Bros. Discovery CEO David Zaslav, Saying He&#8217;s Created &#8216;Zero Value&#8217; After The Conglomerate Announced Plans To Split Into Two Companies By 2026</a>
According <a href="https://www.congress.gov/bill/119th-congress/house-bill/2756/text">to</a> the bill&#8217;s text, the aim is to &#8220;boost biotech funding research/development for biotech products across the country,&#8221; resulting in substantial tailwinds for companies such as IDEXX. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Breaking&#x1f6a8;: A third Politician just bought IDEXX Labs <a href="https://twitter.com/search?q=%24IDXX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$IDXX</a> !! This time it&#39;s Rep. Rob Bresnahan who sits on the House Agriculture Committee Why does that matter? All three of the politicians who bought sit on committees overseeing an Act that would directly benefit the… <a href="https://t.co/5ZZdjbcgGE">pic.twitter.com/5ZZdjbcgGE</a>
&mdash; Nancy Pelosi Stock Tracker &#x265f; (@PelosiTracker_) <a href="https://twitter.com/PelosiTracker_/status/1932466838304342490?ref_src=twsrc%5Etfw">June 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Pelosi Tracker post states that Shreve bought shares on April 6, Delaney followed on April 7, and Bresnahan made his purchase on May 14. While congressional stock trading is legal, it&#8217;s been quite controversial, with <a href="https://www.benzinga.com/trading-ideas/25/05/45552223/exclusive-congress-trading-ban-sees-huge-support-in-reader-poll-heres-the-percent-that-say-let-them-keep-trading-stocks">growing calls for a ban</a> on trading stocks, options and ETFs by members of Congress in recent years.
Why It Matters: Economist Justin Wolfers recently called it &#8220;simply absurd&#8221; that Congressional representatives are <a href="https://www.benzinga.com/news/25/04/44831847/justin-wolfers-when-tweets-move-markets-lawmakers-trading-stocks-is-simply-absurd">allowed to trade stocks</a>, even while receiving &#8220;top secret briefings.&#8221;
It is &#8220;absolutely clear they're using their inside knowledge to get better returns,&#8221; he says, adding that this is not &#8220;how we want to pay our Congressmen.&#8221;
Former House Speaker Nancy Pelosi's portfolio famously outperformed many hedge funds, posting returns of 65% in 2023 and 54% in 2024. But several lesser-known members of Congress have reportedly <a href="https://in.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank?_gl=1&#x2A;70oecc&#x2A;_gcl_au&#x2A;OTU0MzA1MzE4LjE3NDcwMTIxNDM.&#x2A;_ga&#x2A;ZGVsZXRlZA..&#x2A;_ga_V7ZK73W7N0&#x2A;czE3NDk2MjY5MDkkbzE3NCRnMSR0MTc0OTYzMDI4NCRqMjUkbDAkaDA.">achieved even greater gains</a>, between 70% and 149%, fueling public outcry over perceived conflicts of interest.
Price Action: Shares of IDEXX Laboratories were up 1.41% on Tuesday, trading at $525.93, and are down 0.18% after hours.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="147" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11042753/Screenshot-2025-06-11-at-1.57.40-PM-1024x147.png" alt="" class="wp-image-945758" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11042753/Screenshot-2025-06-11-at-1.57.40-PM-1024x147.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11042753/Screenshot-2025-06-11-at-1.57.40-PM-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11042753/Screenshot-2025-06-11-at-1.57.40-PM-768x110.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11042753/Screenshot-2025-06-11-at-1.57.40-PM.png 1534w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
According to Benzinga&#8217;s Edge Stock Rankings, Idexx scores high on Momentum and Growth, but fares poorly on Value and Quality. The stock has a favorable price trend in the short, medium, and long term. Check <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> for deeper insights into the stock, its peers and competitors.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45877457/josh-hawley-peter-welch-propose-raising-federal-minimum-wage-to-15-by-2026-tied-to-inflation">Josh Hawley, Peter Welch Propose Raising Federal Minimum Wage To $15 By 2026, Tied To Inflation</a></li>
</ul>
Photo courtesy: rafapress / Shutterstock.com

Politics

IDXX

Three Lawmakers Bought This Biotech Stock Before Supporting A Bill That Could Boost Its Value: It's Now Up 44%

Analysts' ratings for Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Illumina and provided 12-month price targets. The average target is $103.73, accompanied by a high estimate of $185.00 and a low estimate of $77.00. A decline of 11.21% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1749643271_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Illumina among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$99.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$87.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$114.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$92.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$77.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$112.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Illumina. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Illumina's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Illumina analyst ratings.</a>
<h2>Discovering Illumina: A Closer Look</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>Financial Insights: Illumina</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Illumina's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -3.25% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Illumina's net margin excels beyond industry benchmarks, reaching 12.58%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Illumina's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.53%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Illumina's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.1% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.1, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ILMN

Breaking Down Illumina: 11 Analysts Share Their Views

Intelligent Bio Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) announced an update on its growing footprint in the U.S. Forensic Use Only Market on Wednesday through its strategic <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">partnership with SMARTOX</a>.
SMARTOX, founded in 2012, is a U.S.-based provider of drug and alcohol testing products and services.
It offers a comprehensive portfolio supporting various settings, including healthcare, justice, corporate, and education.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44472191/exclusive-fda-seeks-additional-information-for-intelligent-bio-solutions-drug-screening-system-clearance-process-remains-on-track-for-2025-us-launch" rel="noreferrer noopener">EXCLUSIVE: FDA Seeks Additional Information For Intelligent Bio Solutions&#8217; Drug Screening System, Clearance Process Remains on Track For 2025 US Launch</a>
SMARTOX supports clients across corrections, drug courts, rehabilitation centers, and forensic environments.
In addition to serving clients across the U.S., SMARTOX reaches international markets through its distribution network, including Europe, Latin America, New Zealand, and Australia.
It has deployed over 50 Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including over 1,500 tests in 2024 alone.
INBS&#8217; drug screening technology reduces reliance on invasive methods such as urine or saliva collection while delivering rapid and reliable results directly linked to the individual tested.
As adoption grows in the U.S. Forensic Use Only market, Intelligent Bio continues to actively pursue FDA clearance for its opiate test system for codeine. This effort aims to enable expansion into broader U.S. markets this year, including workplace drug testing, using its innovative fingerprint sweat-based testing technology.
Intelligent Bio reported a third-quarter 2025 loss of 44 cents per share, down from a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45372843/exclusive-intelligent-bio-solutions-q3-gross-profit-jumps-by-91" rel="noreferrer noopener">loss of $1.43 a year ago</a>.
The noninvasive testing solutions provider reported sales of $728.87 thousand, down from $823.80 thousand a year ago.
Total revenues increased 20% quarter-over-quarter, supported by ongoing expansion across safety-critical industries and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">steady customer acquisition</a>.
In March, Intelligent Bio received a patent for its Intelligent Fingerprinting Drug Screening Cartridge in the United States.&nbsp;
This&nbsp;is the company&#8217;s sixth active patent to be granted in the U.S., strengthening the protection of its unique and proprietary <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44491787/exclusive-intelligent-bio-solutions-adds-sixth-us-patent-for-its-drug-screening-technology" rel="noreferrer noopener">drug screening technology</a>.&nbsp;
U.S. Patent (12259385)&nbsp;relates to the proprietary lateral flow test strip inside the company&#8217;s Drug Screening Cartridge.
Price Action: INBS stock is down 5.75% at $1.72 during the premarket session at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45866812/omeros-analyst-sees-1-billion-potential-for-narsoplimab-before-fda-decision" target="_blank" rel="noreferrer noopener">Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision</a></li>
</ul>

Health Care

Contracts

Market-Moving Exclusives

Exclusives

Intelligent Bio Solutions Inc. - Common Stock

INBS

EXCLUSIVE: Intelligent Bio Solutions Expands US Forensic Market Presence, Seeks FDA Clearance For Fingerprint Drug Testing

Across the recent three months, 7 analysts have shared their insights on Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Cognex, presenting an average target of $34.0, a high estimate of $53.00, and a low estimate of $26.00. Experiencing a 12.51% decline, the current average is now lower than the previous average price target of $38.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1749643257_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Cognex. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$29.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Matthew Summerville</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Piyush Avasthy</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$29.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cognex. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Cognex compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Cognex's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Cognex's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CGNX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cognex analyst ratings.</a>
<h2>Unveiling the Story Behind Cognex</h2>
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.
<h3>Cognex: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Cognex's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 2.49%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Cognex's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 10.93%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Cognex's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.59%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Cognex's ROA excels beyond industry benchmarks, reaching 1.2%. This signifies efficient management of assets and strong financial health.
Debt Management: Cognex's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CGNX

Demystifying Cognex: Insights From 7 Analyst Reviews

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $34.0, a high estimate of $47.00, and a low estimate of $23.00. Marking an increase of 0.5%, the current average surpasses the previous average price target of $33.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1749643233_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Travere Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Alex Thompson</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jason Zemansky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Travere Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Travere Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Travere Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Travere Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TVTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Travere Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Travere Therapeutics</h2>
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
<h3>Travere Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Travere Therapeutics displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 97.54%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Travere Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -50.44%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -89.72%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Travere Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -7.21%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Travere Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 12.2, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TVTX

7 Analysts Assess Travere Therapeutics: What You Need To Know

EXCLUSIVE: Intelligent Bio Solutions  Tells Benzinga 'Company continues to actively pursue FDA clearance in connection with planned expansion into broader U.S. markets in 2025'

Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), an advanced nuclear technology company, has been issued a Notice of Intent to Award (NOITA) by the Defense Logistics Agency Energy (DLA Energy), on behalf of the Department of the Air Force (DAF) and the U.S. Department of Defense, to provide clean, reliable power through the deployment of an Aurora powerhouse at the Air Force installation selected for the project.
This project serves as the DAF's microreactor pilot to enhance energy resilience and reliability for critical national security infrastructure. The NOITA again designates Oklo as the apparent successful offeror following a comprehensive evaluation process.
Under the terms of the anticipated agreement, Oklo would design, construct, own, and operate the power plant, delivering both electricity and heat to the DAF's preferred installation, Eielson Air Force Base in Alaska, under a long-term power purchase agreement.

OKLO

Oklo Selected To Provide Clean Nuclear Power For Air Force Base In Alaska Under Defense Department Pilot Program

Jefferies analyst Julien Dumoulin-Smith downgrades Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Hold to Underperform and lowers the price target from $6 to $5.

Downgrades

Jefferies Downgrades Sunrun to Underperform, Lowers Price Target to $5

EXCLUSIVE: Intelligent Bio Solutions  Tells Benzinga Co. Expands U.S. Forensic Market Presence, Says Seeks FDA Clearance For Breakthrough Fingerprint Drug Testing

Jefferies analyst Dennis Ding initiates coverage on Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) with a Hold rating and announces Price Target of $15.

Initiation

MLYS

Jefferies Initiates Coverage On Mineralys Therapeutics with Hold Rating, Announces Price Target of $15

Shares of Elon Musk's EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) continue to rise amid easing tensions between U.S. President Donald Trump and Musk.
What Happened: TSLA stock gained over 2.02% in Pre-Market trading on Wednesday and is now much closer to where it was before the falling out between Musk and Trump.
The stock also gained an impressive 5.67% at close, reaching a value of $326.09 at Market close. However, it is still shy of the $345 mark it was at on Wednesday last week.
Why It Matters: The rally coincides with tensions between Musk and Trump easing as Musk shared how <a href="https://www.benzinga.com/markets/tech/25/06/45877591/elon-musk-says-he-regrets-war-of-words-with-trump-went-too-far">he regrets his outburst</a> on social media platform X. "I regret some of my posts on President Donald Trump last week. They went too far," Musk said.
Musk had criticized Trump's <a href="https://www.benzinga.com/news/25/05/45635854/elon-musk-disappointed-with-trumps-big-beautiful-bill-says-it-undermines-the-work-that-the-doge-team-is-doing">Big Beautiful Bill</a>, adding that the bill could add trillions to the U.S. national debt. He had even referred to the bill as a "disgusting abomination" on one occasion.&nbsp;&nbsp;
Tesla is also gearing up for the Robotaxi launch in Austin, which Musk says will tentatively be available to the <a href="https://www.benzinga.com/markets/tech/25/06/45876375/elon-musk-says-tesla-robotaxi-rides-begin-june-22-in-austin-full-self-driving-to-enable-home-delivery-by-june-28-were-being-super-paranoid">public on June 22</a>. The billionaire also shared that Tesla vehicles would be able to drive to a customer's house from the factory from June 28.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="200" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11071301/TSLA-June-11-2025-1-1-1024x200.jpg" alt="" class="wp-image-945965" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11071301/TSLA-June-11-2025-1-1-1024x200.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11071301/TSLA-June-11-2025-1-1-300x58.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11071301/TSLA-June-11-2025-1-1-768x150.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11071301/TSLA-June-11-2025-1-1-1536x299.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11071301/TSLA-June-11-2025-1-1.jpg 1549w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Tesla scores well on Momentum, Quality and Growth metrics, but offers poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge Stock Rankings</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45878452/why-pro-investor-gary-black-ditched-tesla-to-bet-on-nvidia-amazon-meta-and-doordash">Why Pro Investor Gary Black Ditched Tesla To Bet On Nvidia, Amazon, Meta And DoorDash?</a></li>
</ul>
Image Via Shutterstock

TSLA

Tesla Stock Rally Continues As Share Value Gains Amid Easing Tensions Between Trump And Elon Musk

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is considering a <a target="_blank" href="https://www.benzinga.com/topic/meta-platforms" rel="noreferrer noopener">$15 billion investment</a> in data-labelling startup Scale AI and hiring the group&#8217;s co-founder, Alexandr Wang, and top researchers.
The deal, likely by Wednesday, would give Meta a 49% ownership in Scale AI and value the startup at $28 billion, the Financial Times <a target="_blank" href="https://www.ft.com/content/5e556c2e-2ba4-415a-adb6-1bf6bed498eb" rel="noreferrer noopener">reported</a> on Wednesday, citing unnamed sources familiar with the matter.
<a target="_blank" href="https://www.benzinga.com/m-a/25/06/45839465/zuckerbergs-ai-push-expands-meta-weighs-10b-stake-in-scale-ai" rel="noreferrer noopener">Prior reports indicated</a> Meta may invest over $10 billion in Scale AI.
Also Read: <a href="https://www.benzinga.com/media/25/05/45680165/meta-hits-1-billion-monthly-ai-users-eyes-future-with-subscriptions" target="_blank" rel="noreferrer noopener">Meta Hits 1 Billion Monthly AI Users, Eyes Future With Subscriptions</a>
The move marks Meta&#8217;s plan to build a &#8220;superintelligence&#8221; lab to compete with OpenAI, Anthropic, and Google.
Meta&#8217;s latest large language model, Llama 4, failed to impress with its independent reasoning and coding benchmarks. Meanwhile, competitors such as Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, OpenAI, and Anthropic have showcased advanced &#8220;reasoning&#8221; models.
Meta also faced competition from affordable open-source competitors like China&#8217;s DeepSeek.
In 2024, Meta rivals Microsoft paid $650 million to poach Inflection boss Mustafa Suleyman and their team and to license the startup&#8217;s technology. Google also spent $2.7 billion on a similar arrangement with Character AI.
Reportedly, Meta is <a href="https://www.benzinga.com/markets/tech/25/06/45722563/mark-zuckerbergs-meta-to-offer-fully-automated-ai-based-ad-creation-by-2026-report" target="_blank" rel="noreferrer noopener">considering a system</a> that would enable brands to design and target ads using AI by the end of 2026. Meta&#8217;s current ad platform already uses AI to generate ad variations before targeting users on Facebook and Instagram. 
Meta&#8217;s advertising business is already thriving, with ad impressions increasing by 5% and the average price per ad rising by 10% year-over-year, as reported in its first-quarter results.
Price Action: META stock was trading lower by 0.34% to $700.02 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45561843/meta-offers-ai-startups-free-tools-funding-to-boost-llama-model-adoption" target="_blank" rel="noreferrer noopener">Meta Offers AI Startups Free Tools, Funding To Boost Llama Model Adoption</a></li>
</ul>
Photo by Skorzewiak via Shutterstock

Tech

Media

GOOG

GOOGL

Meta On The Verge Of A $15 Billion Deal With Scale AI: Report

Canaccord Genuity analyst Kyle Mikson maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Hold and raises the price target from $87 to $99.

Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $99

Elon Musk&#8216;s recent public spat with President&nbsp;Donald Trump&nbsp;might have been a strategic move, according to&nbsp;Morgan Stanley analysts.&nbsp;
What Happened: The dispute began when Musk criticized Trump&#8217;s tax bill, resulting in a 14% plunge in Tesla&#8217;s stock and a $150 billion market value loss in a single day. In response, Trump threatened to cancel federal contracts with Musk&#8217;s companies, including SpaceX. At one point, Musk considered decommissioning the Dragon spacecraft but later abandoned the idea. 
"Likely [the feud] part of a planned strategy by Elon to achieve a specific goal with his approach designed to bring maximum public attention to the issue," stated Morgan Stanley, <a href="https://finbold.com/banking-giant-says-trump-v-musk-spat-likely-planned-strategy-updates-tsla-target/?ref=biztoc.com">reported</a> Finbold.
Despite this, Morgan Stanley remains bullish on Tesla, raising its price target from $400 to $410 while reiterating it as their &#8216;top pick&#8217; in the U.S. auto sector. They highlighted Tesla&#8217;s leading position in physical artificial intelligence (AI) and other sectors, stating that Tesla is uniquely positioned in these areas.
The analysts pointed out that Musk's political engagement is now closely linked to Tesla's investment narrative. They warned that investors expecting Musk to concentrate only on Tesla might be ignoring an ongoing trend. &#8220;The two are very much inseparable,&#8221; stated Morgan Stanley as reported by Investing.com.
While acknowledging the possible downsides of Musk's public stance, Morgan Stanley remains confident that Tesla's leadership recognizes and understands these risks.
Morgan Stanley does not foresee any long-term effects of the rift between Musk and Trump.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/equities/25/06/45832827/elon-musks-father-says-trump-will-prevail-blames-sons-feud-mistake-on-stress-as-tesla-stock-slid" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Father Says &#8216;Trump Will Prevail,&#8217; Blames Son&#8217;s Feud &#8216;Mistake&#8217; On Stress As Tesla Stock Slides Nearly 2.5% In Monday Pre-Market</a>
Why It Matters: This feud and its subsequent fallout have been closely watched by investors and analysts alike. Despite the tension, Wedbush Securities&#8217; managing director Dan Ives&nbsp;reiterated his <a href="https://www.benzinga.com/markets/tech/25/06/45830730/dan-ives-remains-bullish-on-tsla-stock-despite-trump-elon-musk-feud-expects-regulatory-framework-for-robotaxis">bullish views </a>on Tesla&nbsp;on June 9. Trump also&nbsp;expressed his intention&nbsp;to <a href="https://www.benzinga.com/markets/tech/25/06/45852837/trump-says-he-wont-ditch-tesla-model-s-or-starlink-as-feud-with-elon-musk-cools-i-wish-him-well">keep his</a> Tesla Model S and Starlink satellite internet service, indicating a cooling of tensions.
On June 11th, Musk <a href="https://www.benzinga.com/markets/tech/25/06/45877591/elon-musk-says-he-regrets-war-of-words-with-trump-went-too-far">expressed regret</a> over his comments about Trump, stating they &#8220;went too far.&#8221; Despite the controversy, Musk deemed the $113 billion loss he incurred while <a href="https://www.benzinga.com/news/politics/25/06/45876964/elon-musk-took-a-113-billion-hit-over-trumps-doge-mission-calls-it-worth-it">working on DOGE</a> &#8220;worth it.&#8221;
These events highlight the complex relationship between politics and business, with potential impacts on investor sentiment and market dynamics. Despite the controversy, Morgan Stanley&#8217;s increased price target indicates continued confidence in Tesla&#8217;s future.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/crypto/cryptocurrency/25/06/45876315/solana-spikes-4-as-report-signals-possible-green-light-for-etf-analyst-sets-approval-odds-at-90" target="_blank" rel="noreferrer noopener">Solana Spikes 4% As Report Signals Possible Green Light For ETF— Analyst Sets Approval Odds At 90% </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump-Musk Feud Likely A 'Planned Strategy,' Says Morgan Stanley, Calling Musk And Politics 'Inseparable' While Staying Bullish On Tesla

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/06/10/final-trades-apple-alphabet-and-quanta-services.html">Halftime Report Final Trades</a>,&#8221; Brenda Vingiello of Sand Hill Global Advisors picked Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) as her final trade.
Lending support to her choice, Piper Sandler analyst Kashy Harrison, on May 27, maintained Quanta Services with an Overweight rating and raised the price target from $360 to $370.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Malcolm Ethridge, Executive Vice President at CIC Wealth Management, said this is the time to buy Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>).
Supporting his view:
<ul class="wp-block-list">
<li>Morgan Stanley analyst Erik Woodring, on Tuesday, reiterated Apple with an Overweight rating and maintained a $235 price target</li>
<li>Wedbush analyst Daniel Ives reiterated the stock with an Outperform rating and maintained a $270 price target. </li>
<li>BofA Securities analyst Wamsi Mohan also reiterated Apple with a Buy and maintained a $235 <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">price target</a>.</li>
</ul>
Alex Kantrowitz named Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), as his final trade.
Alphabet's Google on Tuesday offered buyouts to U.S.-based employees in multiple departments, including the search ads unit. The company extended the voluntary exit program to workers in several divisions, according to CNBC. 
Impacted teams include knowledge and information (K&amp;I), central engineering, marketing, research and communications.
Price Action:
<ul class="wp-block-list">
<li>Apple shares gained 0.6% to close at $202.67 on Tuesday.</li>
<li>Alphabet rose 1.4% to close at $178.60 on Tuesday.</li>
<li>Quanta Services shares fell 1.9% to settle at $348.76 during the session.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2">Top 2 Tech And Telecom Stocks You May Want To Dump In Q2</a></li>
</ul>
Image: Shutterstock

Long Ideas

AAPL

Quanta Services, Apple And Alphabet On CNBC's 'Final Trades'

Canaccord Genuity analyst Carey MacRury initiates coverage on Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) with a Buy rating and announces Price Target of $3.

GROY

Canaccord Genuity Initiates Coverage On Gold Royalty with Buy Rating, Announces Price Target of $3

Matt Hougan, Chief Investment Officer at Bitwise Asset Management on Monday described the surge in public companies holding Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) as a &#8220;megatrend&#8221; that is set to accelerate, driven by concerns over dollar devaluation and <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">growing investor confidence</a>.
What Happened: <a href="https://www.youtube.com/watch?v=i-ZPV6gd3Qc">Speaking</a> on CNBC, Hougan highlighted that 79 public companies now hold $57 billion in Bitcoin, a 160% increase from last year.
Hougan attributed this trend to corporations seeking alternatives to cash and U.S. Treasuries amid record money printing and rising deficits. 
&#8220;Corporations globally are sitting on records amount of cash&#8230; But with the huge money printing and growing deficits, that no longer seems like a valid approach,&#8221; he said. 
Bitcoin, he noted, is seen as &#8220;the best horse in that race&#8221; for protecting wealth.
The Bitwise CIO predicted that thousands of companies will eventually adopt Bitcoin, stating, &#8220;We think we&#8217;re in inning one or two of this megatrend period, but you&#8217;re seeing it accelerate over time.&#8221; 
He also pointed to a structural imbalance in Bitcoin's supply and demand, with ETFs, corporations, and governments absorbing more Bitcoin than the 165,000 produced annually, potentially pushing prices to $200,000 by year-end.
In the interview, Hougan discussed Bitwise's new GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>)-focused covered call ETF, launched to capitalize on the stock's volatility. 
Also Read: <a href="https://www.benzinga.com/news/25/06/45866220/governments-can-use-decentralized-security-without-sacrificing-sovereignty-naoris-ceo-says">Governments Can Use Decentralized Security Without Sacrificing Sovereignty, Naoris CEO Says</a>
He explained that covered call strategies &#8220;translate that volatility into income,&#8221; offering investors a way to maintain exposure while generating returns. 
This approach aligns with Bitwise's broader strategy, including its spot Bitcoin and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) ETFs and pending applications for Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), and XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) ETFs.
What&#8217;s Next: On the regulatory front, Hougan expressed optimism about the Senate's advancement of the <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45604556/scott-bessent-forecasts-stablecoins-increasing-appetite-for-us-treasuries-by-trillions-promises-highest-regulatory-standards-for-dollar-pegged-cryptos">Genius Act stablecoin bill</a>, calling it potentially more significant than the 2024 spot Bitcoin ETF approvals.
&#8220;If we do get there, I think we&#8217;re looking at the longest and most sustained bull market that crypto has seen,&#8221; he said, citing bipartisan support and the U.S. government's need for stablecoins to fund treasuries.
Despite opposition from Senator Josh Hawley, who fears the bill favors big tech, Hougan remains confident it will pass, setting the stage for a multi-year crypto bull market. 
He also highlighted Bitcoin's role in portfolios, noting that its low correlation with stocks and bonds can enhance risk-adjusted returns without increasing volatility.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45865357/ai-agent-collectives-daos-are-overhyped-crypto-narrative-fetch-ai-ceo-says">AI Agent Collectives, DAOs Are Overhyped Crypto Narrative, Fetch.ai CEO Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SOL

$XRP

Public Company Bitcoin Holdings Are A 'Megatrend' Just Getting Started, Says Bitwise's Matt Hougan

Commodities

Small Cap

Press Releases

ReTo Eco-Solutions, Inc. to Hold Its Annual Meeting of Shareholders at Its Headquarters on August 5, 2024 Beijing Time

ReTo Secured Production Line Contract with Middle Eastern Client

ReTo Announces Receipt of Nasdaq Delisting Determination and Plan to Appeal

ReTo Eco-Solutions, Inc. Announces Share Combination

ReTo Regained Compliance with Nasdaq's Minimum Bid Price Requirement

ReTo Eco-Solutions, Inc. Announces Acquisition of Majority Interest in MeinMalzeBier Holdings Limited

Cementos Pacasmayo S.A.A. American Depositary Shares (Each representing five Common Shares)

Comments

ReTo Eco-Solutions

ReTo Eco-Solutions (RETO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO